Wholesale Retatrutide (LY3437943)

Retatrutide (LY3437943) is an investigational triple receptor agonist peptide developed by Eli Lilly, simultaneously targeting the GLP-1, GIP and glucagon receptors. This tri-agonist mechanism distinguishes it from both single GLP-1 agonists such as semaglutide and dual agonists such as tirzepatide, with Phase II data reporting among the highest weight reduction figures seen in any GLP-1 class agent to date. It is currently in Phase II/III clinical development for obesity and metabolic disease.

SARMs-Direct supplies wholesale Retatrutide in lyophilised powder and predosed pen formats to CROs, pharmaceutical R&D groups, universities, clinics and qualified B2B distributors. All supply is strictly for research use only and is not available for human consumption or clinical use.

Retatrutide's tri-agonist mechanism acts on three distinct metabolic receptors simultaneously. GLP-1 receptor agonism reduces appetite and slows gastric emptying. GIP receptor agonism enhances insulin secretion and may improve the tolerability profile of GLP-1 agonism. Glucagon receptor agonism increases hepatic glucose output and, importantly, increases energy expenditure — a mechanism not present in single or dual GLP-1 agonists.

This combined receptor activity is hypothesised to produce additive or synergistic effects on weight reduction and metabolic regulation. Phase II data has reported mean weight reductions of approximately 24% or greater at higher doses over 48 weeks — among the highest figures reported for any agent in this class to date. Research areas include obesity pharmacotherapy, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and cardiometabolic risk factor reduction.